Quadrant Biosciences
World's First Saliva Test for Autism - Available in Clinics Now
Analytics
Raised to Date: $1,004,649
Aggregate Commitments $
Wefunder
02/02/2020
08/15/2020
$50,000
$15,000,000
$501
Equity - Common
RegA+
$266,000,000
Weekly Commitments $
08/26/2020
2,009%
7%
$5,152
976
Healthcare & Pharmaceuticals
Quadrant Biosciences, with a pre-money valuation of $266 million, is raising funds on Wefunder through Reg A+ crowdfunding. The company has launched the world’s first saliva test for autism and is developing a pipeline of products, including tests for schizophrenia, anorexia nervosa, concussion, and Parkinson’s disease. The test for autism, The Clarifi ASD Test, is a game-changer in autism diagnosis and indicates the probability of a child having autism spectrum disorder. Quadrant Biosciences was founded by Richard Uhlig and has raised over $30 million in previous rounds of financing. The current round of crowdfunding has a minimum goal of $50,000 and a maximum goal of $15,000,000, and the proceeds will be used in developing more tests. Quadrant Biosciences has multiple international research partnerships and is working on developing a rapid saliva test for COVID-19.
Balance Sheet
|
Cash and Cash Equivalents |
$3,107,794 |
|
Investment Securities |
$0 |
|
Total Investments |
$0 |
|
Accounts and Notes Receivable |
$116,383 |
|
Loans |
$0 |
|
Property, Plant and Equipment (PP&E) |
$38,292 |
|
Property and Equipment |
$0 |
| Total Assets |
$9,846,764 |
|
Accounts Payable & Accrued Liabilities |
$145,712 |
|
Policy Liabilities and Accruals |
$0 |
|
Deposits |
$0 |
|
Long Term Debt |
$5,304,909 |
|
Total Liabilities |
$5,947,496 |
|
Total Stockholders' Equity |
$3,899,268 |
| Total Liabilities and Equity |
$9,846,764 |
Statement of Comprehensive Income Information
|
Total Revenues |
$343,449 |
|
Total Interest Income |
$0 |
|
Costs & Expenses Applicable to Rev |
$208,446 |
|
Total Interest Expenses |
$0 |
|
Depreciation and Amortization |
$11,331 |
| Net Income |
$-4,840,262 |
|
Earnings Per Share - Basic |
$0 |
|
Earnings Per Share - Diluted |
$0 |
Analyst Report
Ratings Platform - Beta Trial
Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.
For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.Other Deals
UpLyft on Wefunder
UpLyft has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…
HealtheMed on Wefunder
HealtheMed has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…
Millennial Fertility Co. on NetCapital
The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…